You are here:
Two key factors set the GAVI Alliance apart from other actors in the field of international health aid:
In this section, we explain GAVI’s unique business model and the six ways it delivers "added value".
Donor and developing countries need to see proof of the value of new vaccines before investing.
Immunisation is a commitment for life that requires guaranteed, long-term funding.
Developing countries decide for themselves how best to use GAVI support for immunisation.
It's not enough to buy new vaccines. They have to safely reach every child.
Manufacturers will only make vaccines for poor countries if they know they can sell them .
National immunisation programes must survive long after GAVI support stops.
The Accelerated Vaccine Introduction Initiative is a showcase of the GAVI business model at work.
2001: 5 vaccine suppliers to GAVI (1 in an emerging market) | mid-2013: 12 vaccine suppliers to GAVI (over half now based in Africa, Asia, Latin America)
22 January 2014
The toll of the anti-vaccination movement, in one devastating graphic
Los Angeles Times
Public Health Officials Mark 50th Year of Measles Vaccine
16 October 2013
The growth of global immunisation
15 October 2013
Anti-vaccination activists should not be given a say in the media
14 October 2013
Anti-cancer vaccine for Laos
GAVI on Track to Immunize One-Quarter Billion Children by 2015
Voice of America
Parasites: Hookworm Vaccine Will Be Tried in Africa
New York Times
12 October 2013
7 The HPV vaccine: Preventing cervical cancer in the developing world
03 October 2013
AusAid cuts threaten immunisation programs
Nigeria to immunize 35 mln children against measles
© GAVI Alliance 2014
modal window here